UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States

The Journal of dermatological treatment, 2023-12, Vol.34 (1), p.2200870-2200870

2023

Volltextzugriff (PDF)

Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry

The Journal of dermatological treatment, 2024-12, Vol.35 (1), p.2287401-2287401

2024

Volltextzugriff (PDF)

Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States

The Journal of dermatological treatment, 2023-12, Vol.34 (1), p.2200869-2200869

2023

Volltextzugriff (PDF)

Uncovering the burden of hidradenitis suppurativa misdiagnosis and underdiagnosis: a machine learning approach

Frontiers in medical technology, 2024-03, Vol.6, p.1200400-1200400

2024

Volltextzugriff (PDF)

Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis

Journal of comparative effectiveness research, 2018-10, Vol.7 (10), p.959-974

2018

Volltextzugriff (PDF)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors

Indian journal of endocrinology and metabolism, 2011-07, Vol.15 (Suppl 1), p.S69-S70

Garg, Vishvas

2011

Volltextzugriff (PDF)

Noninsulin pharmacological management of type 1 diabetes mellitus

Indian journal of endocrinology and metabolism, 2011-07, Vol.15 (Suppl 1), p.S5-S11

Garg, Vishvas

2011

Volltextzugriff (PDF)

51441 Real-World Switch Rates in Patients with Psoriasis Treated with Biologics Over 3 Years in the United States

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB295-AB295

2024

Volltextzugriff (PDF)

41279 Real-World Switch Rates of Biologics and Associated Costs in Patients With Psoriasis

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB81-AB81

2023

Volltextzugriff (PDF)

Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study

Advances in therapy, 2019-07, Vol.36 (7), p.1672-1683

2019

Volltextzugriff (PDF)

51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB59-AB59

2024

Volltextzugriff (PDF)

43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB189-AB189

2023

Volltextzugriff (PDF)

44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB62-AB62

2023

Volltextzugriff (PDF)

Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review

Advances in therapy, 2019-08, Vol.36 (8), p.1851-1877

2019

Volltextzugriff (PDF)

Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry

Journal of the American Academy of Dermatology, 2024-01, Vol.90 (1), p.82-90

2024

Volltextzugriff (PDF)

Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting

Clinical therapeutics, 2017-08, Vol.39 (8), p.1600-1617

2017

Volltextzugriff (PDF)

34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB200-AB200

2022

Volltextzugriff (PDF)

P224 A matching-adjusted indirect comparison (MAIC) of upadacitinib versus tofacitinib in csDMARD-IR patients with moderate to severe RA

Rheumatology (Oxford, England), 2020-04, Vol.59 (Supplement_2)

2020

Volltextzugriff (PDF)

Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany

Clinical therapeutics, 2017-08, Vol.39 (8), p.1618-1627

2017

Volltextzugriff (PDF)

Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project

Journal of bone and joint surgery. American volume, 2013-02, Vol.95 (4), p.297-307

2013

Volltextzugriff (PDF)

Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis

Advances in therapy, 2021-10, Vol.38 (10), p.5302-5316

2021

Volltextzugriff (PDF)

Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient Registry

Arthritis care & research (2010), 2016-07, Vol.68 (7), p.914-921

2016

Volltextzugriff (PDF)

Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world

Clinical and experimental rheumatology, 2017-09, Vol.35 (5), p.791

2017

Volltextzugriff (PDF)

Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study

Advances in therapy, 2018-05, Vol.35 (5), p.655-665

2018

Volltextzugriff (PDF)

Life-threatening dermatologic adverse events in oncology

Anti-cancer drugs, 2014-02, Vol.25 (2), p.225-234

2014

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(41)
Dissertationen
(1)

Sprache

Englisch
(42)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States

Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry

Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States

Uncovering the burden of hidradenitis suppurativa misdiagnosis and underdiagnosis: a machine learning approach

Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis

Health economic evaluation of dipeptidyl peptidase-4 inhibitors

Noninsulin pharmacological management of type 1 diabetes mellitus

51441 Real-World Switch Rates in Patients with Psoriasis Treated with Biologics Over 3 Years in the United States

41279 Real-World Switch Rates of Biologics and Associated Costs in Patients With Psoriasis

Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study

51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry

43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review

Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry

Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting

34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry

P224 A matching-adjusted indirect comparison (MAIC) of upadacitinib versus tofacitinib in csDMARD-IR patients with moderate to severe RA

Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany

Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project

Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis

Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient Registry

Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world

Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study

Life-threatening dermatologic adverse events in oncology

Suchergebnisse filtern